Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
> Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in
FullYear
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
– COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation
Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights
Cash position of €62 million at year-end provides runway until the end of H2 2022
DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments
Montrouge, France, March 11, 2021 DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business
22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020
Key Business and Financial Highlights 22nd Century has a tremendous global commercial opportunity in the
Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights
− Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First
Spero Therapeutics to Present Company Update and Report Fourth Quarter and Full-Year 2020 Monetary Success on Thursday, March 11, 2021
CAMBRIDGE, Mass., March 03, 2021 (World NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
Target Corporation Reports Fourth Quarter and Full-Year 2020 Earnings
MINNEAPOLIS, March 2, 2021 /PRNewswire/ — Q4 2020 Highlights Comparable sales grew 20.5 percent, reflecting